BACKGROUND: Good reporting of experimental research is a vital part of research process. Although the reporting guidelines such as Animal research: Reporting in vivo experiments (ARRIVE) require the authors to stick to a standard format, they do not guarantee study reports' validity. For assessing the study reports validity, critical appraisal tools are required.
Introduction

R
eplication of preclinical studies' results in humans has been disappointing. There may be two likely explanations behind this. To begin with, animals are intricate living creatures. Second, the methodological nature of animal research (AR) may be deficient, causing ambiguous outcomes. [1] There is considerable corroboration that reporting of experimental research is less than optimal. [2] Moreover, the low replication of ARs can be ascribed to insufficient reporting. Thus, optimal reporting of experimental research is an essential part of any research. [3] In view of these confirmations, there have been demands for improved reporting in AR. [4] The Animal research: Reporting in vivo experiments (ARRIVE) statement in 2010 epitomized a key step to ameliorate the reporting standard of AR. [5, 6] The ARRIVE guidelines recommend addition of the methodological factors that have been found to be inadequately reported in animal experiments. Application of ARRIVE may result in enhanced reporting quality of AR (though there is a report contrary to that). [7] Although the reporting guidelines require the authors to stick to a standard format, they do not guarantee the study validity. [5] The poor reporting of animal experiments, due to compromised internal and external validity, has been implicated in the divergences between the results of preclinical and clinical studies. [8] Validity of the report can be evaluated by critical appraisal tools. [9] It is imperative to appraise the internal as well as external validity to judge whether outcomes of the study represent the source and target population. Internal as well as external validity can be assessed through critical appraisal. [10] Indian Journal of Pharmacology (IJP) is a globally recognized and highly respected journal. Majority of studies published in IJP consist of in vivo AR. It was thus sensible to evaluate in vivo animal studies adherence to ARRIVE guidelines and to evaluate the methodological quality of the in vivo animal studies through critical appraisal. [11, 12] 
Objective
The evaluation of the methodological quality of in vivo animal studies published in IJP from 2011 to 2017 through critical appraisal was the primary objective. The secondary objective of was to evaluate the adherence of the published in vivo animal studies to the ARRIVE guidelines.
Materials and Methods
Study design
This was a retrospective, cross-sectional, observational study to evaluate the methodological quality of in vivo animal studies through critical appraisal and to examine their adherence to ARRIVE guideline. The ethical committee sanction was not obligatory because this study completely relies on the information accessible in the public domain and is a quality audit not incorporating sensitive information retrieval.
Data extraction
All in vivo animal studies published as full-text articles in IJP from January 2011 to December 2017 and fulfilling the eligibility criteria were eligible for inclusion. Eligible articles were identified by screening of titles, abstracts, keywords, and methodology.
Eligibility criteria Inclusion criteria
(1) Animal studies with treatment intervention, (2) only original research articles, and (3) studies published between January 2011 and December 2017.
Exclusion criteria (1) In vitro experiments, (2) studies on animals that were dead before inception of the study, (3) studies where no intervention was performed, (4) studies with no control group, and (5) review articles, commentaries, communications or correspondences, and short communication.
Assessment of adequacy of reporting and critical appraisal of evidences
The assessment of reporting of the in vivo animal experiments was done by guiding principles on the ARRIVE statement. A checklist was prepared dependent on the ARRIVE statement [Tables 1 -5] . [6, 13] Some items on the checklists were added based on a study by Muhlhausler et al., 2013 . [5] The checklist was applied to in vivo AR published in IJP. For critical appraisal of reports, risk-of-bias domains were also applied on studies from in vivo AR. [10, 14] The in-depth appraisal of AR's methodology, management, and analysis was done to determine its validity.
Data analysis
An exploratory and descriptive statistical analysis was done. Descriptive statistics was applied to illustrate the reporting of studies, as well as for the key methodological items. The SPSS statistical software package (SPSS for Windows, Version 16.0. Chicago, SPSS Inc.) was utilized for statistical analysis. Criteria's were demarcated as "yes" if they were unambiguously reported or "no" if they were indistinct or not stated at all. The lower and upper limits of the 95% confidence interval (CI) for the proportions was calculated.
Results
Overall, 1185 articles from IJP between January 2011 and December 2017 were screened for suitability. Figure 1 explains the retrieval and selection of articles in the present study. Out of the total 1185 articles, the screening of title and abstracts excluded 637 articles. These 637 articles included Drug watch (190); Letters to editor or correspondences (144); Short communications (118); Education forum and review articles (54); Editorials (46); and others (n = 85), i.e., Abstracts (29), Book reviews (18), Case reports (13), Obituaries (11), Errata (7), Announcements (4), Special 
Discussion
In critical appraisal, the most common characteristic contemplated is internal validity. [15] If the outcomes derived from study population are indicative of the source population, then the study is assumed to be valid internally. The major hazard to internal validity is the risk of bias. [10, 14] In in vivo AR, selection bias arises when nonrandom factors impact the distribution of animals to study interventions. Selection bias happens if detected variances between the groups in the study are attributable to the confounder rather than interventions. Randomization is the optimum tool for distribution of confounders across the intervention groups in equal proportion. [10] In this study, 45.34% of articles gave details about randomization. In a study by Kilkenny et al. 2009 , 12% of all studies reported randomization of animals to experimental groups. [3] In a review by Hess 2011, 28% studies reported about randomization of animals. [16] In a methodological study of AR by Bara and Joffe 2014, 61% of all studies gave details about randomization. [1] Performance bias happens when there are logical differences between experimental groups in susceptibility to determinant apart from the study intervention. [10] Allocation concealment can be used to prevent performance bias. [17] Random housing of the animal can also be used to prevent performance bias. [14] In this study, none of the studies reported allocation concealment mechanism. In a study by Bara and Joffe 2014, 6% of the studies reported allocation concealment. [1] Whereas in a study by Hirst et al. 2014 , 15% of studies conveyed it. [18] Detection bias can ensue if there are variances in outcome assessment methods between treatment groups. [10, 17] It can be avoided by blinding of the persons evaluating the outcome. [10] In this study, 11.18% of the study reported blinding. In a study by Bara and Joffe 2014, 40% of all studies stated about blinding. [1] Macleod et al. 2015 reported about blinding in 29.5% of animal studies. [19] In a study by Kilkenny et al. 2009 , only 14% of all included study reported about blinding. [3] Attrition bias is a problem in clinical research but the likelihood for discretionary attrition bias in in vivo AR is practically nil. However, nondiscretionary attrition can unintentionally introduce bias. [10] The commonly used tool to prevent attrition bias is reporting dropouts. In this study, animal number in each experimental group included in the analysis was given by all studies. None of the article in this study gave details about any dropout or explain why they were not included in the analysis. In the report by Hotwani et al. 2017 , 91% of the study reported the animal number in each experimental group included in the analysis. [12] External validity defines whether outcomes of the study represent the target population. O'Connor and Sargeant stated that if the study results are internally valid, then it will represent the target population. [10] There are no guidelines for assessing external validity of AR. [10] This study does not offer any insight into the external validity of the studies analyzed. This study had several limitations. The included studies were diverse with respect to the study outcomes, animals used, and disease types. Some studies may have failed to report some methodological details when in fact these were used. This study only assesses the reporting quality of assessed studies and did not aim to evaluate the quality of conduct.
Conclusion
Overall, this study demonstrated good adherence of in vivo AR studies published in IJP with respect to the ARRIVE statement with few exceptions. It was found that adherence to only some criteria of ARRIVE guidelines was subpar. There is a necessity for optimal reporting of random distribution of animals to experimental groups, concealment of allocation, blinded outcome evaluation, computation of sample size, and reporting of attrition of animals for improving validity of AR.
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